Result for
Topic: Vaccines and Immunity
April 12, 2021
Antibody Responses in Elderly Residential Care Persons Following COVID-19 MRNA Vaccination
[Pre-print, not peer-reviewed] While all fully vaccinated long-term care residents (n = 70) in a cross-sectional study in the Pittsburg region between March 15 and April 1, 2021 had detectable SARS-CoV-2 antibodies, levels tended to be lower among those who were male, older, used steroid medications, or had a longer length of time since vaccination….
Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2 MRNA Vaccinated Individuals
[Pre-print, not peer-reviewed] A case-control study of individuals with SARS-CoV-2 infection in Israel who received the Pfizer vaccine (cases) versus unvaccinated carriers (controls) found that the predominant SARS-CoV-2 variant among vaccine recipients with a positive SARS-CoV-2 PCR result differed depending on their timing in the vaccine course. Compared to controls, vaccinated individuals infected at least…
Early Evidence of COVID-19 Vaccine Effectiveness within the General Population of California
[Pre-print, not peer-reviewed] Fully immunized individuals (either Pfizer-BioNTech or Moderna) experienced 86% protection against SARS-CoV-2 infection, and partial protection was observed following the first dose (66%) and in the first two weeks after receipt of a second dose (78%) in a case-control study conducted from February 24 to April 7, 2021. Cases were defined by…
April 9, 2021
Poor Anti-SARS-CoV-2 Humoral and T-Cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept
A study of kidney transplant recipients receiving belatacept (N=101), a drug to prevent organ rejection, found that humoral and T-cell immune response to the Pfizer-BioNTech vaccine was low. Only 2 patients developed spike antibodies 28 days after the first dose and 2 of 35 patients tested one month after the 2nd dose developed antibodies. A…
Single-Dose BNT162b2 Vaccine Protects against Asymptomatic SARS-CoV-2 Infection
A study of health care workers (N=~9,000) employed at Cambridge University Hospitals in Great Britain found that 1 dose of the Pfizer-BioNTech COVID-19 vaccine was associated with a 4-fold reduction in asymptomatic SARS-CoV-2 infection ≥12 days post-vaccination, from 0.8% to 0.2% [EDITORIAL NOTE: This is equivalent to a 75% vaccine efficacy]. Additionally, the median cycle…
April 8, 2021
Humoral and Cellular Immunogenicity of the BNT162b2 MRNA Covid-19 Vaccine in Nursing Home Residents
Nursing home residents who had a prior SARS-CoV-2 infection were more likely than those with no history of infection to have an immunologic response within 1 week of the second dose of the Pfizer-BioNtech vaccine. Among nursing home residents in Belgium, humoral and cellular responses elicited by vaccination with the Pfizer-BioNtech vaccine were detected in…
COVID-19 Vaccine Hesitancy among Individuals with Cancer Autoimmune Diseases and Other Serious Comorbid Conditions
[Pre-print, not peer-reviewed] Nearly 1 in 5 individuals with serious comorbid conditions expressed COVID-19 vaccine hesitancy in an international cross-sectional survey conducted from January to February 2021. Participants (n=22,000, 74% from the US) were randomly sampled from Inspire, a large online health community of individuals with comorbid conditions. 10% of participants declared they would not…
Single Prime HAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2
[Pre-print, not peer-reviewed] Phase 1b trials for a novel adenovirus-vector COVID-19 vaccine (hAd5-S-Fusion+N-ETSD developed by ImmunityBio) containing the SARS-CoV-2 antigen spike (S) and nucleocapsid (N) proteins demonstrated a 10-fold increase in mean S- and N-specific T-cell responses from patients (n=4) with prior SARS-CoV-2 infection after a single dose. For context, currently approved vaccines only target…
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
Antibody responses to the B.1.351 SARS-CoV-2 variant (aka, 501Y.V2) in a cohort of patients hospitalized with COVID-19 in South Africa (n=89) were found to be robust and showed high levels of cross-reactivity against the virus strain from the first wave. Furthermore, sera from patients infected with B.1.351 also neutralized the P.1 variant (aka, 501Y.V3) first…
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
A single dose of the Pfizer-BioNTech vaccine substantially increased neutralizing activity against SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 among healthcare workers (HCWs) previously infected with SARS-CoV-2 (n=6). Serum samples from each HCW were obtained 1-12 weeks after natural infection, immediately before vaccination, and 1-2 weeks after vaccination and were tested using a microneutralization assay containing…
Previous page Next page